ST高升(000971) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥117,631,933.60, an increase of 4.19% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was -¥25,842,016.66, a decrease in loss of 77.26% year-on-year[5]. - The total operating revenue for Q3 2023 was CNY 354,580,693.74, an increase of 7.5% compared to CNY 331,094,770.66 in the same period last year[23]. - The net loss for Q3 2023 was CNY 36,927,091.72, compared to a net loss of CNY 242,553,248.43 in Q3 2022, indicating an improvement in financial performance[24]. - The basic and diluted earnings per share for Q3 2023 were both -0.03, compared to -0.23 in the same quarter last year[26]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥68,784,431.74, an increase of 155.09% compared to the previous year[5]. - Operating cash flow for the current period is ¥68,784,431.74, a significant improvement from the previous period's negative cash flow of -¥124,848,923.64[27]. - Total cash inflow from operating activities decreased to ¥548,778,316.15 from ¥589,853,339.02 in the previous period, reflecting a decline of approximately 7.5%[27]. - Cash outflow from operating activities decreased to ¥479,993,884.41, down from ¥714,702,262.66, indicating a reduction of about 32.8%[27]. - Net cash flow from investment activities improved to ¥14,684,336.98 from a negative cash flow of -¥51,695,321.73 in the previous period[28]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,244,044,748.54, a decrease of 6.36% from the end of the previous year[5]. - The total assets as of Q3 2023 amounted to CNY 1,244,044,748.54, down from CNY 1,328,514,611.06 at the end of the previous quarter[21]. - The total liabilities decreased to CNY 1,035,588,218.65 from CNY 1,083,130,989.45, reflecting a reduction of approximately 4.4%[21]. - The total equity attributable to shareholders of the parent company decreased to CNY 192,792,964.29 from CNY 228,861,225.27[21]. Research and Development - The company's R&D expenses increased by 31.48% year-on-year, amounting to ¥25,329,490.78[9]. - Research and development expenses increased to CNY 25,329,490.78 from CNY 19,265,482.63, showing a growth of approximately 31.6% year-over-year[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,866[11]. - The controlling shareholder has increased its stake by acquiring 965,100 shares, representing 0.09% of the total share capital[16]. - The company’s major shareholders include Tianjin Baoruo Ke Pharmaceutical Biotechnology Co., holding 15.21% of shares, and Yiwu Rongze Investment Management Co., holding 8.60%[12]. - The company has not disclosed any related party transactions among its top shareholders[12]. Risks and Warnings - The company is under risk warning due to unresolved issues related to guarantees and fund occupation[14]. - The company reported a total of ¥21,010.36 million in outstanding guarantees and non-operating fund occupation as of the report date[14]. Accounting and Auditing - The company has not undergone an audit for the third quarter report[29]. - The new accounting standards were first implemented in 2023, affecting the financial statements[29].